Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rituximab and Cladribine in Newly Diagnosed Mantle Cell Lymphoma
NCT00053027Phase 2Completed
- Sponsor
- Cancer and Leukemia Group B
- Start
- Feb 2003
- Primary completion
- Jan 2006
- Modality
- Small Molecules, Monoclonal Antibodies
01
Overview
Phase 2, open-label, single-arm trial of rituximab and cladribine in mantle cell lymphoma (MCL), sponsored by Cancer and Leukemia Group B. Primary endpoint: Complete Remission and Complete Remission Unconfirmed Rate up to 4 years. Started Feb 2003; status: completed.
02
Drugs
rituximabcladribine
03
Conditions
mantle cell lymphoma (MCL)
Beyond the preview
Go deeper on NCT00053027.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00053027.